Atea Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Atea Pharmaceuticals

29/02/2024 02:27

* Atea Pharmaceuticals Inc  AVIR.OQ  reported a quarterly
adjusted
loss of 47 cents​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of -41 cents.  The mean expectation of four analysts for the
quarter was for a loss of 50 cents per share. Wall Street
expected results to range from -52 cents to -48 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Atea Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 47 cents​.
    * The company reported a quarterly loss of $38.7 million.
    * Atea Pharmaceuticals Inc shares had risen by 49.5% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 2.8%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and 2 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Atea
Pharmaceuticals Inc is $3.00 
This summary was machine generated from LSEG data February 29 at
02:26 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.50          -0.47          Beat
 Sep. 30 2023      -0.48          -0.40          Beat
 Jun. 30 2023      -0.47          -0.34          Beat
 Mar. 31 2023      -0.48          -0.43          Beat